Cell & Gene Therapy Bioanalytical Testing Services Market to Grow with a CAGR of 8.85% through 2030
Increasing investment in cell
and gene therapy research and development and the rising prevalence of
genetic and rare diseases are factors driving the global Cell & Gene
Therapy Bioanalytical Testing Services market in the forecast period 2026-2030.
According to TechSci Research report, “Cell &
Gene Therapy Bioanalytical Testing Services Market – Global Industry Size,
Share, Trends, Competition Forecast & Opportunities, 2030”, the
Global Cell & Gene Therapy Bioanalytical Testing Services Market stood at
USD 523.26 Million in 2024 and is anticipated to grow with a CAGR of 8.85% in
the forecast period through 2030. The field of cell and gene therapy has
witnessed unprecedented growth and innovation over the past decade. These
cutting-edge therapies hold the promise of revolutionizing the treatment of
various diseases by harnessing the power of genetics and cellular biology. As
the cell and gene therapy industry continues to advance, the demand for robust
bioanalytical testing services has surged.
One of the primary drivers of the Global
Cell & Gene Therapy Bioanalytical Testing Services Market is the
significant investment in research and development (R&D) within the cell
and gene therapy sector. Both pharmaceutical companies and biotechnology firms
are pouring substantial resources into developing innovative therapies to
address previously untreatable diseases, such as genetic disorders and certain
cancers. To ensure the safety, efficacy, and quality of these therapies,
comprehensive bioanalytical testing services are essential. Consequently, this
investment in R&D fuels the demand for specialized testing services.
The prevalence of genetic and rare diseases is on the
rise globally. Patients suffering from these conditions often have limited
treatment options, making cell and gene therapies a ray of hope. Bioanalytical
testing is crucial in the development and manufacturing of these therapies,
ensuring they meet regulatory standards and are safe for patient use. The
growing need for specialized testing to support the development of therapies
for these conditions is a significant market driver.
Regulatory agencies around the world,
including the U.S. Food and Drug Administration (FDA) and the European
Medicines Agency (EMA), have recognized the potential of cell and gene
therapies and have established regulatory pathways for their approval. These
agencies require rigorous testing and analysis to ensure the safety and
efficacy of these therapies. As a result, companies engaged in cell and gene
therapy development must collaborate with specialized bioanalytical testing
service providers to meet these regulatory requirements, further propelling
market growth.
Advancements in analytical technologies
have enabled more precise and comprehensive bioanalytical testing. These
technologies include next-generation sequencing (NGS), mass spectrometry, and
flow cytometry, among others. These cutting-edge tools allow for the in-depth
analysis of cellular and genetic components, providing valuable insights during
the development and production of cell and gene therapies. The adoption of
these advanced technologies has increased the demand for specialized testing
services.
The cell and gene therapy industry has
seen a surge in collaborations and partnerships between pharmaceutical
companies, biotech firms, academic institutions, and research organizations.
These collaborations often involve global players coming together to leverage
their expertise and resources. Such collaborations require standardized and
high-quality bioanalytical testing services to ensure consistency and
reliability across different locations, thereby driving the demand for testing
services on a global scale.
As more cell and gene therapies receive
regulatory approval and reach the market, patient awareness is increasing.
Patients and their healthcare providers are increasingly seeking these
innovative therapies as treatment options. To gain market approval and patient
trust, companies must invest in robust testing services to demonstrate the
safety and efficacy of their therapies.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Cell& Gene Therapy Bioanalytical Testing Services Market.”
The Global Cell & Gene Therapy Bioanalytical
Testing Services Market is segmented into Test Type, Product Type, Stage of Development , Indication, Regional Distribution and Company.
Based on Indication, the Oncology segment stands out as the fastest-growing category within the Cell & Gene Therapy Bioanalytical Testing Services Market. This growth is primarily fueled by the escalating global incidence of cancer, which has intensified the demand for innovative and effective treatment modalities. Cell and gene therapies, particularly those involving gene-modified cells like CAR-T and CAR-NK therapies, have shown significant promise in targeting and eliminating cancer cells. These advanced therapies necessitate comprehensive bioanalytical testing to ensure their safety, efficacy, and regulatory compliance. As a result, there is an increasing reliance on specialized bioanalytical services to support the development and validation of these treatments. The complexity of oncology-related therapies, coupled with the need for precise and reliable testing methodologies, underscores the pivotal role of bioanalytical services in this domain. Consequently, the oncology indication is experiencing rapid growth, reflecting the broader trend towards personalized medicine and targeted cancer therapies.
Based on Region, the Asia Pacific region is experiencing the fastest growth in the Cell & Gene Therapy Bioanalytical Testing Services Market, driven by a combination of factors that enhance its appeal for research and development activities. Countries such as China, India, Japan, and South Korea are at the forefront, benefiting from substantial investments in healthcare infrastructure and a surge in clinical trials related to cell and gene therapies. The region's cost-effective outsourcing options and a large, diverse patient population make it an attractive destination for pharmaceutical and biotechnology companies seeking efficient and economical testing services. Moreover, supportive government policies and funding initiatives are fostering an environment conducive to advanced therapeutic research. The increasing prevalence of chronic diseases, including cancer and genetic disorders, further amplifies the demand for innovative treatments, thereby propelling the need for comprehensive bioanalytical testing services. As a result, the Asia Pacific region is not only accelerating in market growth but also establishing itself as a pivotal hub for the advancement of cell and gene therapy solutions
Major companies operating in
Global Cell & Gene Therapy Bioanalytical Testing Services Market
are:
- BioAgilytix Labs Inc.
- KCAS Bioanalytical & Biomarker
Services
- IQVIA, Inc.
- Laboratory Corporation of America
Holdings
- Thermo Fisher Scientific Inc.
- Prolytix pvt ltd
- Pharmaron Biologics (UK) Ltd
- Charles River Laboratories
International, Inc.
- Syneos Health Ltd
- Intertek Group Plc
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“The Global Cell & Gene Therapy Bioanalytical
Testing Services Market is poised for sustained growth due to several key
market drivers. These include increasing investments in R&D, the rising
prevalence of genetic and rare diseases, supportive regulatory frameworks,
advancements in analytical technologies, global collaborations, and growing
patient awareness and demand. As the cell and gene therapy field continues to
evolve and expand, bioanalytical testing services will remain a critical
component, ensuring the development and delivery of safe and effective therapies
to patients in need.,” said Mr. Karan Chechi, Research Director of TechSci
Research, a research-based management consulting firm.
“Cell & Gene Therapy Bioanalytical Testing
Services Market By
Test Type (Bioavailability & Bioequivalence Studies, Pharmacokinetics,
Pharmacodynamics, Other test Stage of Development), Product Type ( Gene
Therapy, Gene-Modified Cell Therapy, Cell Therapy), By Stage of Development
(Non-Clinical, Clinical), By Indication (
Oncology, Infectious Diseases, Neurological disorders, Rare Diseases, Others), By
Region and Competition, 2020-2030F”, has evaluated the future growth potential of Global
Cell & Gene Therapy Bioanalytical Testing Services Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cell & Gene Therapy Bioanalytical
Testing Services Market.
Contact
TechSci Research LLC
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: sales@techsciresearch.com
Website: https://www.techsciresearch.com